Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Psychotropic Prescription Patterns for Inpatients with Schizophrenia : 10-Year Comparison in a University-Affiliated Hospital in South Korea

조현병 환자의 입원 치료시 약물처방 경향의 변화 : 일 대학병원에서 1996~2000년과 2006~2010년의 차이 비교

  • Hwang, In-Hwan (Department of Psychiatry, Hanyang University Medical Center) ;
  • Kim, Daeho (Department of Psychiatry, Hanyang University Medical Center) ;
  • Oh, Dae-Young (Department of Psychiatry, Bundang CHA Medical Center, CHA University)
  • 황인환 (한양대학교 의료원 정신건강의학과) ;
  • 김대호 (한양대학교 의료원 정신건강의학과) ;
  • 오대영 (CHA의과학대학교 분당차병원 정신건강의학교실)
  • Received : 2014.02.24
  • Accepted : 2014.04.09
  • Published : 2014.05.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives Previous literature on the prescription change among patients with schizophrenia mainly focused on antipsychotics. This study investigated chronological change in the patterns of discharge medication among inpatients with schizophrenia at a psychiatric inpatient unit of a university-affiliated hospital. Methods All admission records at a psychiatric unit of Hanyang University Guri Hospital with discharge diagnosis of schizophrenia during two different five-year time frames (1996-2000 and 2006-2010) were reviewed including the demographic and clinical data and discharge medications. The data were gathered from a total of 207 patients (95 in 1990s and 112 in 2000s). Results The frequency in use of atypical antipsychotics (p < 0.01), antidepressants (p < 0.05), beta-blockers (p < 0.01), and benzodiazepine (p < 0.01) was significantly higher in 2000s. Anticholinergic drugs were less likely used in 2000s (p < 0.01). We did not find significant differences in the equivalent dose of antipsychotic drugs, the use of mood stabilizers and cholinergic drugs between two time frames. Conclusions Increased proportion of atypical antipsychotics and decreased use of anti-parkinsonian drugs are in line with literature. Our results show that more diverse classes of psychotic medications are used for schizophrenia in recent years. It is likely that psychiatrists are becoming more conscious of negative symptoms, anxiety, and depression in the pharmacotherapy of schizophrenia as well as positive symptoms of the illness.

Keywords

References

  1. Turner MS, Stewart DW. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol 2006; 20(6 Suppl):20-37. https://doi.org/10.1177/1359786806071243
  2. Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012;12:20. https://doi.org/10.1186/1471-244X-12-20
  3. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2010;71 Suppl 2:20-26. https://doi.org/10.4088/JCP.9096su1cc.04
  4. Friedman JH. Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology 2003;28 Suppl 1:39-51.
  5. Kwon JS, Ahn YM, Kim JH. Korean Medication Guideline for Schizophrenia 2006. Seoul: Korean Medication Algorithm Task Force for Schizophrenia;2006.
  6. Roh D, Chang JG, Kim CH, Cho HS, An SK, Jung YC. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust N Z J Psychiatry 2014;48:52-60. https://doi.org/10.1177/0004867413488221
  7. Best-Shaw L, Gudbrandsen M, Nagar J, Rose D, David AS, Patel MX. Psychiatrists' Perspectives on Antipsychotic Dose and the Role of Plasma Concentration Therapeutic Drug Monitoring. Ther Drug Monit (in press).
  8. Jung HJ, Kim D, Oh HY, Park YC. Patterns of delusions and hallucinations in schizophrenia: comparison between the 1990s and the 2000s. Korean J Biol Psychiatry 2013;20:80-85.
  9. Oh HY, Kim D, Park YC. Nature of Persecutors and Their Behaviors in the Delusions of Schizophrenia: Changes between the 1990s and the 2000s. Psychiatry Investig 2012;9:319-324. https://doi.org/10.4306/pi.2012.9.4.319
  10. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667. https://doi.org/10.4088/JCP.v64n0607
  11. Rijcken CA, Monster TB, Brouwers JR, de Jong-van den Berg LT. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol 2003;23: 657-659. https://doi.org/10.1097/01.jcp.0000096247.29231.3a
  12. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010;67:255-262. https://doi.org/10.1016/j.biopsych.2009.08.040
  13. Shim IH, Woo YS, Jun TY, Kim KS, Bahk WM. Changes in antipsychotic drug usage in the psychiatric inpatients at a university hospital between 1997, 2003-2004 and 2009-2010. Korean J Psychopharmacol 2012;23:57-64.
  14. Kwon JS, Kim ET, Ha TH, Roh KS, Choi JS, Kim YS. Drug prescribing patterns of outpatients with schizophrenia in a university hospital. J Korean Neuropsychiatr Assoc 2003;42:683-690.
  15. Choi HJ, Jung SH, Kang MH, Lee JS, Bae JN, Kim CE. Antipsychotics prescribing patterns of patients with schizophrenia admitted to Korean general hospital psychiatric unit: 2001 to 2008. Clin Psychopharmacol Neurosci 2011;9:17-22. https://doi.org/10.9758/cpn.2011.9.1.17
  16. Sim K, Lee NB, Chua HC, Mahendran R, Fujii S, Yang SY, et al. Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study. Br J Clin Pharmacol 2007;63:431-437. https://doi.org/10.1111/j.1365-2125.2006.02780.x
  17. Gilmer TP, Dolder CR, Folsom DP, Mastin W, Jeste DV. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007; 58:1007-1010. https://doi.org/10.1176/ps.2007.58.7.1007
  18. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003;37:55-61. https://doi.org/10.1046/j.1440-1614.2003.01110.x
  19. Santamaría B, Pérez M, Montero D, Madurga M, de Abajo FJ. Use of antipsychotic agents in Spain through 1985-2000. Eur Psychiatry 2002;17:471-476. https://doi.org/10.1016/S0924-9338(02)00705-8
  20. Micallef J, Fakra E, Blin O. [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale 2006;32(2 Pt 1):263-269. https://doi.org/10.1016/S0013-7006(06)76153-X
  21. Acosta FJ, Aguilar EJ, Cejas MR, Gracia R. Beliefs about illness and their relationship with hopelessness, depression, insight and suicide attempts in schizophrenia. Psychiatr Danub 2013;25:49-54.
  22. Kao YC, Liu YP. Suicidal behavior and insight into illness among patients with schizophrenia spectrum disorders. Psychiatr Q 2011;82: 207-220. https://doi.org/10.1007/s11126-010-9161-z
  23. Jovanovic N, Podlesek A, Medved V, Grubisin J, Mihaljevic-Peles A, Goran T, et al. Association between psychopathology and suicidal behavior in schizophrenia. A cross-sectional study of 509 participants. Crisis 2013;34:374-381. https://doi.org/10.1027/0227-5910/a000211
  24. Gorna K, Jaracz K, Wrzyszczynska L, Rybakowski F. Quality of life and depression in schizophrenic patients. Adv Med Sci 2007;52 Suppl 1:108-111.
  25. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24. https://doi.org/10.1097/00131746-200701000-00003
  26. Gaillard R, Ouanas A, Spadone C, Llorca PM, Loo H, Bayle FJ. [Benzodiazepines and schizophrenia, a review of the literature]. Encephale 2006;32(6 Pt 1):1003-1010. https://doi.org/10.1016/S0013-7006(06)76280-7
  27. Bayle FJ, Blanc O, De Chazeron I, Lesturgeon J, Lancon C, Caci H, et al. [Pharmacological management of anxiety in patients suffering from schizophrenia]. Encephale 2011;37 Suppl 1:S83-S89. https://doi.org/10.1016/j.encep.2010.08.009
  28. Rashkis HA, Smarr ER. Protection against reserpine-induced Parkinsonism. Am J Psychiatry 1957;113:1116. https://doi.org/10.1176/ajp.113.12.1116
  29. Cancelli I, Beltrame M, Gigli GL, Valente M. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci 2009;30:87-92. https://doi.org/10.1007/s10072-009-0033-y
  30. Straker M. Clinical factors in tardive-dyskinesia. Psychiatr J Univ Ott 1980;5:28-33.
  31. Rahiminejad F, Akhondzadeh S. Pharmacotherapy of schizophrenia: ploypharmacy approaches. Acta Med Iran 2010;48:203-208.
  32. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010;17:460-466. https://doi.org/10.1097/MED.0b013e32833de61c